Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.44 |
| ▸ | FAAH | O00519 | 9/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728585 | 1.00 | KMT2A (0.52) | KMT2AALDH1A1HPGDL3MBTL1TRPA1 | |
| SCHEMBL5680680 | 0.90 | ALDH1A1 (0.61) | KMT2AALDH1A1HPGD | |
| SCHEMBL5680683 | 0.90 | ALDH1A1 (0.61) | KMT2AALDH1A1HPGD | |
| SCHEMBL20824903 | 0.86 | ALDH1A1 (0.68) | KMT2AALDH1A1HPGD | |
| SCHEMBL20417359 | 0.86 | ALDH1A1 (0.57) | KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL19439614 | 0.83 | GRIN2D (0.47) | KMT2AALDH1A1CYP1A2 | |
| SCHEMBL14196484 | 0.82 | KMT2A (0.53) | KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL21975288 | 0.82 | ALDH1A1 (0.53) | KMT2AALDH1A1HPGD | |
| SCHEMBL9810599 | 0.82 | ALDH1A1 (0.57) | KMT2AALDH1A1ENPP2CYP1A2 | |
| SCHEMBL9810590 | 0.82 | ALDH1A1 (0.57) | KMT2AALDH1A1ENPP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691803-A1 | N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS | Warner-Lambert Company LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005056004-A1 | N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | HMGCR, DHCR7, CYP11A1 | KMT2A 2864/4885ALDH1A1 1452/4885HPGD 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.